Sep 12, 2022 / 11:00AM GMT
Emily Bodnar - H.C. Wainwright & Co. - Analyst
Hello, everyone, and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference on September 12-14. My name is Emily Bodnar, and I'm an equity research analyst at H.C. Wainwright. While we are hybrid this year, confident that we are going to be able to provide value to you with over 550 companies presenting at this conference.
Please join us for one-on-one meetings, corporate presentations and panels that will be available live and streaming on September 12-14. With that said, I'd like to introduce Jeffrey Eisenberg, who is the Chief Executive Officer of Xenetic Biosciences, which is focused on developing innovative immune-oncology technologies.
Jeffrey Eisenberg - Xenetic Biosciences, Inc. - CEO
Emily, thank you very much and thanks to you and all your colleagues for inviting us to participate in this investor conference. Really appreciate it. And thank you all for joining this morning as well, whether it's live or on the replay. So I will be of course, making forward
Xenetic Biosciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers